ARA-290 is a piece of erythropoietin engineered so that it cannot do what erythropoietin is famous for. Erythropoietin drives red blood cell production through one receptor and, it was later found, tissue-protective signalling through a different one. ARA-290 is an eleven-residue peptide taken from the region of the hormone that engages the second receptor and not the first. It is one of the clearest examples in the catalogue of a fragment designed to keep one activity and discard another — and a useful test of whether that design premise holds.
Two receptors, one hormone
Erythropoietin is a 165-residue glycoprotein hormone. Its classical action, stimulating red cell production in bone marrow, runs through a homodimer of the erythropoietin receptor. That receptor has high affinity and is the one every textbook describes.
The second receptor was proposed later. In tissues under stress, erythropoietin receptor subunits were found paired not with each other but with the β-common receptor subunit shared by several cytokine receptors. This heterodimer — named the innate repair receptor by the group that characterised it — has lower affinity for erythropoietin, is expressed in response to injury rather than constitutively, and its signalling was associated with anti-inflammatory and tissue-protective effects rather than with blood.
Which part of erythropoietin was ARA-290 taken from?
Helix B. Erythropoietin folds into four helices, and the surface of helix B faces away from the classical receptor's binding sites and toward where the β-common subunit was proposed to sit. Eleven residues from that surface were synthesised as a linear peptide and found to retain activity at the heterodimer while showing none at the homodimer. The name it later carried in clinical development is cibinetide. The logic is the same one behind AOD-9604 and KPV: locate the region responsible for one activity, cut it out, and leave the rest behind.
| Erythropoietin | ARA-290 | |
|---|---|---|
| Size | 165 residues, glycosylated | 11 residues, linear |
| Classical receptor (homodimer) | Binds, drives red cell production | No measurable activity |
| Innate repair receptor (heterodimer) | Binds, lower affinity | Binds |
| Half-life | Hours | Minutes |
| Made by | Recombinant expression | Solid-phase synthesis |
Why would anyone want the tissue-protective activity without the blood activity?
Because the blood activity is the problem in that context. Erythropoietin's classical effect raises red cell mass, which thickens blood and carries its own risks, and that effect is what limits any use of the hormone for its other properties. A molecule engaging only the heterodimer can in principle be studied for tissue-protective signalling without that confound. Whether the separation is as clean in a living system as it is at the receptor is an empirical matter, and it is the question the compound exists to ask.
Reading the literature
ARA-290 has an unusual profile for this catalogue: a defined receptor with a proposed structure, a mechanism that can be tested with receptor-null systems, and a history of clinical development under its other name. That is a stronger footing than most short peptides have. Two cautions still apply.
The receptor itself is contested. The innate repair receptor was characterised principally by one research group, and its existence as a distinct functional entity has been questioned by others in the erythropoietin field. Work on ARA-290 inherits that debate. A result consistent with the heterodimer model is not proof of the heterodimer; the strongest experiments are those using cells lacking the β-common subunit as a control.
The half-life is minutes. It is an unmodified linear peptide with free termini, and it is cleared and degraded rapidly. The literature reports activity persisting well beyond the peptide's presence, which is interpreted as the receptor triggering a durable programme rather than needing sustained occupancy — a plausible reading, and one that should be tested rather than assumed.
Does ARA-290 need a receptor-negative control?
More than most compounds do, precisely because the receptor is disputed. A response to ARA-290 in a cell line expressing both the erythropoietin receptor and the β-common subunit is consistent with the model; the same response in a line lacking the β-common subunit would contradict it, and its absence there would support it. Without that comparison, an experiment shows that the peptide does something and cannot say through what. For a compound whose whole identity is receptor selectivity, that is the experiment.
How should it be handled?
As a short, unmodified, water-soluble peptide, with the exposures those words imply. No cysteine, so no dimerisation; but eleven residues with free termini is a short-lived solution in any protease-containing medium, and a small molecule with proportionally large surface losses at working concentrations. Fresh dilutions, low-binding tubes, and timing between addition and readout recorded as a variable. The compound is stable dry; it is the solution that is perishable.
Is ARA-290 the same as cibinetide?
Yes — one is the research code and the other the name assigned during clinical development. The two naming systems answer different questions, and here the presence of a development name is itself informative: it marks a molecule that went through formal evaluation, which is more than most catalogue peptides can say, without implying that any of that evaluation applies to research use.
Why eleven residues, and not the whole helix?
Because the aim was to capture a surface, not a fold. Helix B in the intact hormone is held in shape by the rest of the protein; excised on its own, a stretch of that length does not remain helical in solution, so there was no structure to preserve by taking more of it. The eleven residues were chosen as the minimal stretch that retained activity at the heterodimer in the original screens, which is the same reasoning that produced every minimal active fragment in this catalogue. It also means ARA-290 in solution is an unstructured linear peptide presenting a sequence, and any activity it has comes from that sequence being recognised rather than from mimicking the hormone's shape.
All products referenced here are supplied for laboratory and research use only. They are not drugs, foods, supplements or cosmetics, and are not for human or veterinary use.
